| Project/Area Number |
25861668
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatric surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
Nakahata Kengo 大阪大学, 医学部附属病院, 医員 (50643532)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 癌幹細胞 / アルデヒド脱水素酵素1 / 横紋筋肉腫 / ジスルフィラム / 血管新生阻害 / アルデヒド脱水素酵素１ |
|---|
| Outline of Final Research Achievements |
Recent studies have demonstrated that aldehyde dehydrogenase 1 (ALDH1) is a marker for cancer stem cells (CSCs) in adult cancers. We examined the characteristics of the cells with a high ALDH1 activity (ALDH1high cells) in rhabdomyosarcoma (RMS). We used the human embryonal RMS (ERMS) cell lines RD and KYM-1, and sorted the cells into two subpopulations: ALDH1high cells, and cells with a low ALDH1 activity (ALDH1low cells). To demonstrate that ALDH1high cells have stronger CSC characteristics than ALDH1low cells, we performed both in vitro and in vivo assays. ALDH1high cells comprised 3.9% and 8.2% of the total RD and KYM-1 cells, respectively. ALDH1high cells showed a higher capacity for self-renewal and tumor formation. With regard to chemoresistance, the survival rate of ALDH1high cells was higher following treatment with chemotherapeutic agents for RMS.
We confirmed that ALDH1high RD and KYM-1 cells had characteristics of CSCs, and that ALDH1 is a potential marker of CSCs in eRMS.
|
